Read by QxMD icon Read

intratumoral chemotherapy lung cancer

Lin Shi, Xiangdong Wang
Patients with lung cancer still have high mortality, recurrence rate after adjuvant treatment, and poor five-year survival rates, despite of advances in multidisciplinary anti-cancer therapies, e.g. chemotherapy, radiotherapy and targeted therapies, It depends upon the presence of intratumoral heterogeneity and complexity of lung cancer. There is growing evidence to suggest that osteopontin (OPN) may play a critical role in tumor progression and metastasis. The present review briefly describes the structure and molecular biology of OPN, highlights the role of OPN in the development and metastasis of lung cancer, and summarizes potential mechanisms of OPN heterogeneity in tumor to underline some of these inconsistencies...
August 28, 2016: Seminars in Cell & Developmental Biology
Jun-Jie Ma, Hui-Ping Liu
OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC), and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. METHODS: Totally 150 patients with NSCLC were randomly assigned to the control group, the intravenous group and the intratumor group by the random envelope method, 50 cases in each group...
August 2, 2016: Chinese Journal of Integrative Medicine
Jarrod D Predina, Jane Keating, Ollin Venegas, Sarah Nims, Sunil Singhal
Non-small Cell Lung Cancer (NSCLC) remains a deadly disease despite aggressive treatment protocols which incorporate chemotherapy, radiation and surgery. These traditional approaches have reached a plateau in therapeutic benefit. There is emerging evidence suggesting that immunotherapy can serve as an alternative treatment modality for NSCLC. Our group has nearly two decades of experience involving immuno-gene therapy with Ad.hIFN-α and Ad.hIFN-β in human mesothelioma trials, and has observed both safety and efficacy in treatment of Thoracic malignancies...
April 2016: Discovery Medicine
Weijian Feng, Jin Li, Suhong Han, Jinfeng Tang, Jie Yao, Yuqing Cui, Chuntang Wang, Zhongcheng Chen, Xiaoguang Li, Xiuyi Zhi
BACKGROUND: Radiofrequency ablation (RFA) has become one of the local treatment for inoperable early stage non-small cell lung cancer (NSCLC). This study observes effectiveness and safety of computed tomography (CT) guided RFA followed intratumoral chemotherapy (RFA-ITC). METHODS: From 2005 to 2015, our group perspectively enrolled inoperable early stage NSCLC underwent RFA-ITC duo to poor cardiopulmonary function or with other diseases or patient can't tolerate or reject surgery...
May 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
Elizabeth A Guancial, Deepak Kilari, Guang-Qian Xiao, Sohaib H Abu-Farsakh, Andrea Baran, Edward M Messing, Eric S Kim
BACKGROUND: Platinum (Pt)-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, resistance is a major limitation. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our group previously demonstrated a significant correlation between tissue Pt concentration and tumor response to Pt-based neoadjuvant chemotherapy (NAC) in lung cancer. We hypothesized that increased Pt concentration in radical cystectomy (RC) specimens would correlate with improved pathologic response to Pt-based NAC in MIBC...
2016: PloS One
Xiaoming Luo, Guisen Xu, Jiaojun Wei, Maohua Chen, Hong Zhang, Xiaohong Li
Cancer progression and metastasis relies much on vasculature networks in tumor microenvironment, and the combination treatment with chemotherapeutic drugs and vascular disrupting agents represents apparent clinical benefits. In the current study, fiber fragments with loadings of hydroxycamptothecin (HCPT) or combretastatin A-4 (CA4) were proposed for tumor inhibition and blood vessel disruption after local administration in tumors. To address challenges in balancing the disruption of tumor vessels and intratumoral uptake of chemotherapeutic agents, this study is focus on release tuning of HCPT and CA4 from the fiber fragment mixtures...
June 15, 2016: International Journal of Pharmaceutics
Gerald S M A Kerner, Vikram R Bollineni, Thijo J N Hiltermann, Nanna M Sijtsema, Alexander Fischer, Alphons H H Bongaerts, Jan Pruim, Harry J M Groen
BACKGROUND: Hypoxia is associated with resistance to chemotherapy and radiotherapy and is randomly distributed within malignancies. Characterization of changes in intratumoral hypoxic regions is possible with specially developed PET tracers such as (18)F-fluoroazomycin arabinoside ((18)F-FAZA) while tumor metabolism can be measured with 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG). The purpose of this study was to study the effects of chemotherapy on (18)F-FAZA and (18)F-FDG uptake simultaneously in non-small-cell lung cancer (NSCLC) patients METHODS: At baseline and after the second chemotherapy cycle, both PET/CT with (18)F-FDG and (18)F-FAZA was performed in seven patients with metastasized NSCLC...
December 2016: EJNMMI Research
Karen Foguer, Marina de Souza Braga, Jean Pierre Schatzmann Peron, Karina Ramalho Bortoluci, Maria Helena Bellini
BACKGROUND: Renal cell carcinoma (RCC) is a highly vascularized cancer resistant to chemotherapy and radiotherapy. RCC is frequently infiltrated with immune cells, with macrophages being the most abundant cell type. Alternatively activated M2 macrophages are known to contribute to tumor progression. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we investigated the impact of ES gene therapy on the polarization of tumor-associated macrophages (TAMs) in lung metastases from tumor-bearing mice...
April 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Farshad Ramazani, Cornelis F van Nostrum, Gert Storm, Fabian Kiessling, Twan Lammers, Wim E Hennink, Robbert J Kok
Locoregional delivery of anticancer drugs is an attractive approach to minimize adverse effects associated with intravenous chemotherapy. Polymer-based drug depots injected or implanted intratumorally or adjacent to the tumor can provide long-term local drug exposure. This review highlights studies in which drug-eluting depots have been applied locally in the treatment of cancer. In many cases such drug depots are used for prevention of tumor recurrence after surgery to eradicate remaining tumor cells. Clinical success has been reported for the treatment of brain cancer and liver cancer, and preclinical studies showed proof-of-concept for inhaled drug depots in lung cancer and intraperitoneally injected depots for the treatment of abdominal cancer...
April 2016: Drug Discovery Today
Nicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A Wilson, Nicolai J Birkbak, Crispin T Hiley, Thomas B K Watkins, Seema Shafi, Nirupa Murugaesu, Richard Mitter, Ayse U Akarca, Joseph Linares, Teresa Marafioti, Jake Y Henry, Eliezer M Van Allen, Diana Miao, Bastian Schilling, Dirk Schadendorf, Levi A Garraway, Vladimir Makarov, Naiyer A Rizvi, Alexandra Snyder, Matthew D Hellmann, Taha Merghoub, Jedd D Wolchok, Sachet A Shukla, Catherine J Wu, Karl S Peggs, Timothy A Chan, Sine R Hadrup, Sergio A Quezada, Charles Swanton
As tumors grow, they acquire mutations, some of which create neoantigens that influence the response of patients to immune checkpoint inhibitors. We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity. Through integrated analysis of ITH and neoantigen burden, we demonstrate a relationship between clonal neoantigen burden and overall survival in primary lung adenocarcinomas. CD8(+)tumor-infiltrating lymphocytes reactive to clonal neoantigens were identified in early-stage non-small cell lung cancer and expressed high levels of PD-1...
March 25, 2016: Science
Andrea Casadei Gardini, Marita Mariotti, Alessandro Lucchesi, Sara Pini, Martina Valgiusti, Sara Bravaccini, Angelo Del Monte, Marco Angelo Burgio, Giorgia Marisi, Dino Amadori, Giovanni Luca Frassineti
BACKGROUND: Small-cell lung cancer (SCLC) is known to express antigens of both the neural crest and epithelium, and to secrete polypeptide hormones and enzymes. Anecdotal reports correlate lung cancer with marked hyperamylasemia, and a review of the literature reveals only one case of metastatic SCLC linked to high paraneoplastic lipase production. CASE PRESENTATION: We present the case of a patient with metastatic SCLC who showed both lipase and pancreatic isoamylase elevation in the absence of acute pancreatitis...
2016: BMC Cancer
Chun Huang, Xuan Wang, Jing Wang, Li Lin, Zhujun Liu, Wenjing Xu, Liuchun Wang, Jianyu Xiao, Kai Li
BACKGROUND: Antiangiogenesis plays a key role in the treatment of non-small lung cancer (NSCLC). We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. METHODS: Our study included 105 untreated NSCLC patients who received Endostar in combination with NP chemotherapy at the Tianjin Lung Cancer Center...
September 2014: Thoracic Cancer
Vivek Mittal, Tina El Rayes, Navneet Narula, Timothy E McGraw, Nasser K Altorki, Mary Helen Barcellos-Hoff
The tumor microenvironment (TME) represents a milieu that enables tumor cells to acquire the hallmarks of cancer. The TME is heterogeneous in composition and consists of cellular components, growth factors, proteases, and extracellular matrix. Concerted interactions between genetically altered tumor cells and genetically stable intratumoral stromal cells result in an "activated/reprogramed" stroma that promotes carcinogenesis by contributing to inflammation, immune suppression, therapeutic resistance, and generating premetastatic niches that support the initiation and establishment of distant metastasis...
2016: Advances in Experimental Medicine and Biology
Gal Shafirstein, Athar Battoo, Kassem Harris, Heinz Baumann, Sandra O Gollnick, Joerg Lindenmann, Chukwumere E Nwogu
Photodynamic therapy (PDT) is an established treatment modality for non-small cell lung cancer. Phototoxicity, the primary adverse event, is expected to be minimized with the introduction of new photosensitizers that have shown promising results in phase I and II clinical studies. Early-stage and superficial endobronchial lesions less than 1 cm in thickness can be effectively treated with external light sources. Thicker lesions and peripheral lesions may be amenable to interstitial PDT, where the light is delivered intratumorally...
February 2016: Annals of the American Thoracic Society
Yuichi Fujimoto, Shinsaku Togo, Miniwan Tulafu, Kazue Shimizu, Takuo Hayashi, Toshimasa Uekusa, Yuichirou Honma, Yukiko Namba, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki, Kazuhisa Takahashi
BACKGROUND: Lung adenocarcinoma is often composed of a complex and heterogeneous mixture of histological subtypes. Invasive adenocarcinomas are now classified by their predominant pattern, using the comprehensive histological subtyping of the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) classifications. This study aimed to determine whether the expression levels of predictive chemotherapy biomarkers are associated with the histological subtypes proposed by the IASLC/ATS/ERS classification...
2015: International Journal of Clinical and Experimental Pathology
Gabriela Garrastazu Pereira, Amanda Jane Lawson, Francesca Buttini, Fabio Sonvico
Lung cancer poses one of the most significant challenges to modern medicine, killing thousands every year. Current therapy involves surgical resection supplemented with chemotherapy and radiotherapy due to high rates of relapse. Shortcomings of currently available chemotherapy protocols include unacceptably high levels of systemic toxicity and low accumulation of drug at the tumor site. Loco-regional delivery of nanocarriers loaded with anticancer agents has the potential to significantly increase efficacy, while minimizing systemic toxicity to anticancer agents...
November 20, 2015: Drug Delivery
Hiren J Mehta, Abbie Begnaud, Andrea M Penley, John Wynne, Paras Malhotra, Sebastian Fernandez-Bussy, Jessica M Cope, Jonathan J Shuster, Michael A Jantz
PURPOSE: A common pattern of recurrence in lung cancer after receiving full dose external beam radiation therapy (EBRT) to targeted sites is isolated mediastinal and hilar recurrence (IMHR). Treatment options for these patients are limited to palliative radiation, chemotherapy, and/or best supportive care. We describe our experience with treating IMHR with bronchoscopic endobronchial ultrasound (EBUS) guided intratumoral injection of cisplatin (ITC). METHODS: Patients treated between Jan 2009-September 2014 with ITC for IMHR were included...
December 2015: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Junli Zeng, Jie Yin, Dongmei Yuan, Wen Yang, Wenjun Liang, Guannan Wu, Yong Song
PURPOSE: Nab-paclitaxel [nab-P, 130 nm albumin-bound paclitaxel particles] is a new solvent-free paclitaxel that allows for high intratumoral concentration and has been approved for use in various solid tumours. The aim of our study was to evaluate the efficacy and safety of nab-paclitaxel in the treatment of advanced non-small-cell lung cancer [NSCLC] . PATIENTS AND METHODS: We assessed 101 Chinese patients who were diagnosed with Stage IIIB or IV NSCLC from August 2009 to November 2014...
September 25, 2015: Clinical Respiratory Journal
Min Zhou, Jun Zhao, Mei Tian, Shaoli Song, Rui Zhang, Sanjay Gupta, Dongfeng Tan, Haifa Shen, Mauro Ferrari, Chun Li
Tumor Initiating Cells (TICs) are resistant to radiotherapy and chemotherapy, and are believed to be responsible for tumor recurrence and metastasis. Combination therapies can overcome the limitation of conventional cancer treatments, and have demonstrated promising application in the clinic. Here, we show that dual modality radiotherapy (RT) and photothermal therapy (PTT) mediated by a single compartment nanosystem copper-64-labeled copper sulfide nanoparticles ([(64)Cu]CuS NPs) could suppress breast tumor metastasis through eradication of TICs...
December 14, 2015: Nanoscale
Masaomi Kuwada, Yoshitomo Chihara, Yi Luo, Xiangru Li, Yukiko Nishiguchi, Rina Fujiwara, Takamistu Sasaki, Kiyomu Fujii, Hitoshi Ohmori, Kiyohide Fujimoto, Masuo Kondoh, Hiroki Kuniyasu
Bladder cancer displays an aggressive phenotype in the muscle-invasive phase, and is associated with a high mortality rate. Therefore, novel molecular therapeutic targets are needed to improve patient survival. A monoclonal antibody against the extracellular domain of the claudin-4 (CLDN4) tight junction protein was established by immunizing rats with a plasmid vector encoding human CLDN4. A hybridoma clone, producing a rat monoclonal antibody recognizing CLDN4 (clone 4D3), was obtained. Immunohistochemistry by using the 4D3 antibody showed that CLDN4 expression was associated with local invasion, nodal metastasis, distant metastasis, and advanced stage in 86 cases of bladder cancer...
December 1, 2015: Cancer Letters
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"